Health Care Archives - Page 34 of 478

2 minute read

Drugmaker Sanofi’s Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings

April 25, 9:47 AM

Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent to hit €13 billion in 2024 sales. Blockbuster ambitions for Beyfortus.

SNY

2 minute read

AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance

By Vandana Singh

April 25, 9:03 AM

AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal 2024 outlook: low double-digit revenue and EPS growth.

AZN

2 minute read

What’s Going On With Palantir Technologies Today?

By Nabaparna Bhattacharya

April 25, 7:55 AM

Palantir Technologies (PLTR) shares dip premarket despite multi-year partnership with Parexel to enhance clinical trials efficiency using AI platforms.

PLTR

1 minute read

EXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes

By Vandana Singh

April 25, 7:45 AM

Unlock the potential of adaptive immunity with ImmuneSelect by Virax Biolabs. Investigate T-Cell driven immunity for post-viral syndromes like Long COVID. Explore peptide pools and recombinant antibodies for immune profiling.

VRAX

2 minute read

McKinsey Faces Criminal Probe By DOJ For Opioid Consulting: Report

By Benzinga Neuro

April 25, 1:05 AM

The U.S. Department of Justice is conducting a criminal investigation into the consulting firm McKinsey & Company for its role in advising major opioid manufacturers on increasing sales. The investigation also focuses on potential obstruction of justice related to McKinsey's consulting records for opioid producers.

MCK

2 minute read

Viking Therapeutics Reports Q1 Results: ‘An Exceptional Period’ Says CEO

By Erica Kollmann

April 24, 5:19 PM

Viking Therapeutics reports quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.14%. Research and development expenses were $24.1 million for the first quarter, compared to $11 million for the same period in 2023.

VKTX

2 minute read

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

By Vandana Singh

April 24, 2:29 PM

Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN-978 potential for autoimmune diseases, particularly systemic lupus erythematosus.

AMGN

2 minute read

Biogen/Eisai’s Popular Alzheimer’s Drug Leqembi Is Seeing Slow Adoption – Here’s Why

By Vandana Singh

April 24, 2:23 PM

Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA approval.

BIIB

2 minute read

Humana Withdraws Its Already Lowered 2025 Profit Guidance

By Vandana Singh

April 24, 2:18 PM

Humana revises 2025 profit forecast due to disappointing Medicare Advantage reimbursement rates. Medical benefit ratio up to 88.9% in Q1 2024. Adjusted EPS growth outlook impacted by pricing decisions for 2025 MA bids.

HUM

2 minute read

What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk

By Vandana Singh

April 24, 2:14 PM

Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could impact millions, tackling accessibility challenges amidst rising costs.

LLY